H. Odabas Et Al. , "Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology," TUMOR BIOLOGY , vol.36, no.12, pp.9641-9648, 2015
Odabas, H. Et Al. 2015. Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology. TUMOR BIOLOGY , vol.36, no.12 , 9641-9648.
Odabas, H., Ulas, A., Aydin, K., İNANÇ, M., Aksoy, A., Yazilitas, D., ... Turkeli, M.(2015). Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology. TUMOR BIOLOGY , vol.36, no.12, 9641-9648.
Odabas, Hatice Et Al. "Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology," TUMOR BIOLOGY , vol.36, no.12, 9641-9648, 2015
Odabas, Hatice Et Al. "Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology." TUMOR BIOLOGY , vol.36, no.12, pp.9641-9648, 2015
Odabas, H. Et Al. (2015) . "Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology." TUMOR BIOLOGY , vol.36, no.12, pp.9641-9648.
@article{article, author={Hatice Odabas Et Al. }, title={Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology}, journal={TUMOR BIOLOGY}, year=2015, pages={9641-9648} }